for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Insulet Corporation

PODD.OQ

Latest Trade

155.80USD

Change

3.21(+2.10%)

Volume

440,926

Today's Range

152.46

 - 

157.00

52 Week Range

70.82

 - 

168.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
152.59
Open
152.53
Volume
440,926
3M AVG Volume
15.67
Today's High
157.00
Today's Low
152.46
52 Week High
168.00
52 Week Low
70.82
Shares Out (MIL)
60.27
Market Cap (MIL)
8,922.62
Forward P/E
480.49
Dividend (Yield %)
--

Next Event

Q3 2019 Insulet Corp Earnings Release

Latest Developments

More

Insulet Says Priced Private Placement Of $700 Mln Aggregate Principal Amount Of Convertible Senior Notes Due 2026

Insulet Announces Private Offering Of Convertible Senior Notes

Insulet Q2 Earnings Per Share $0.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.

Industry

Medical Equipment & Supplies

Contact Info

100 Nagog Park

+1.978.6007000

https://www.myomnipod.com

Executive Leadership

Timothy J. Scannell

Independent Chairman of the Board

Shacey Petrovic

President, Chief Executive Officer, Director

Wayde D. McMillan

Chief Financial Officer, Executive Vice President

Charles Alpuche

Chief Operating Officer, Executive Vice President

Bret Christensen

Executive Vice President and Chief Commercial Officer

Key Stats

1.83 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.4K

2017

0.5K

2018

0.6K

2019(E)

0.7K
EPS (USD)

2016

-0.480

2017

-0.460

2018

0.050

2019(E)

0.308
Price To Earnings (TTM)
553.07
Price To Sales (TTM)
13.67
Price To Book (MRQ)
35.65
Price To Cash Flow (TTM)
241.98
Total Debt To Equity (MRQ)
243.15
LT Debt To Equity (MRQ)
243.15
Return on Investment (TTM)
2.12
Return on Equity (TTM)
1.91

Latest News

BRIEF-Ypsomed Holding Initiates Arbitration Proceedings Against Insulet Corp.

* CONTINUES TO ESTIMATE EXPIRATION FEE TO AMOUNT TO APPROXIMATELY CHF 50 MILLION Source text: https://bit.ly/2ECtzDJ Further company coverage: (Gdynia Newsroom)

BRIEF-Insulet Reports Q1 Loss Per Share $0.11

* INSULET REPORTS FIRST QUARTER 2018 REVENUE OF $123.6 MILLION, UP 21% YEAR-OVER-YEAR, AND GROSS MARGIN OF 61.4%, UP 300 BASIS POINTS, EXCEEDING EXPECTATIONS

BRIEF-Insulet Establishes Two Significant Commercial Partnerships To Support Its European Expansion

* INSULET ESTABLISHES TWO SIGNIFICANT COMMERCIAL PARTNERSHIPS TO SUPPORT ITS EUROPEAN EXPANSION

BRIEF-Insulet Corp Says CEO's 2017 Total Compensation Was $8.2 Mln Vs $6 Mln In 2016

* INSULET CORP SAYS CEO PATRICK J. SULLIVAN'S 2017 TOTAL COMPENSATION WAS $8.2 MLN VS $6 MLN IN 2016 – SEC FILING Source text: (https://bit.ly/2EsXkmY) Further company coverage:

BRIEF-Insulet Corp Posts Q4 Loss Per Share $0.12

* INSULET REPORTS FOURTH QUARTER REVENUE OF $130.5 MILLION, UP 26%, AND GROSS MARGIN UP 210 BASIS POINTS, EXCEEDING EXPECTATIONS

BRIEF-Ascensia Diabetes Care Enters Strategic Alliance With Insulet Corp

* ASCENSIA DIABETES CARE EXPANDS STRATEGIC ALLIANCE WITH INSULET CORPORATION BY SIGNING COMMERCIAL AGREEMENT

BRIEF-Insulet announces pricing of convertible senior notes due 2024

* Insulet announces pricing of convertible senior notes due 2024

BRIEF-Insulet announces private offering of convertible senior notes

* Insulet announces private offering of convertible senior notes

BRIEF-Insulet Corp reports Q3 loss per share $0.04

* Q3 revenue $121.8 million versus I/B/E/S view $114.4 million

BRIEF-Insulet says $100 mln investment in Massachusetts will provide for hundreds of local jobs

* Says $100 million investment in Massachusetts will provide for hundreds of local manufacturing jobs at a 350,000 square-foot facility

BRIEF-Insulet Corp appoints two board of directors

* Insulet Corporation appoints Michael R. Minogue and James C. Mullen to board of directors Source text for Eikon: Further company coverage:

BRIEF-Insulet reports Q2 loss per share $0.13

* Q2 revenue $109.8 million versus I/B/E/S view $106.2 million

BRIEF-Ypsomed to separate from Insulet

* TO SEPARATE FROM INSULET AND EXTEND ITS PORTFOLIO WITH AN OWN PATCH PUMP IN MID-TERM

BRIEF-Insulet to assume distribution and commercial support for its Omnipod system in Europe

* Insulet to assume distribution and commercial support for its Omnipod system in Europe

BRIEF-Insulet presents positive omnipod horizon hybrid closed-loop study results in children

* Insulet presents positive omnipod® horizon™ hybrid closed-loop study results in children

BRIEF-Insulet announces positive results from feasibility study of diabetes drug

* Announced positive results from first feasibility study of omnipod horizon(tm) hybrid closed-loop system Source text for Eikon: Further company coverage:

BRIEF-Insulet Q3 loss per share $0.05 from continuing operations

* Q3 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S

BRIEF-Insulet says Patrick Sullivan elected chairman of board

* Says Jessica Hopfield, PHD, assumes role of lead independent director

BRIEF-Insulet enrolls first patients in clinical trial for its Omnipod artificial pancreas system

* Enrolls first patients in clinical trial for its Omnipod artificial pancreas system Source text for Eikon: Further company coverage:

BRIEF-Insulet announces pricing of convertible senior notes due 2021

* Insulet announces pricing of convertible senior notes due 2021

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up